Glerup M, et al. - Between 1997 and 2000 from defined geographic areas in Denmark, Norway, Sweden, and Finland, authors estimated 510 candidates to assess the long-term progression, remission rate and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset. They recorded the ERA category of JIA having the highest median score, 4.5 and the median juvenile arthritis disease activity (JADAS71) score, 1.5. They noticed 46% of cases with active disease, and 66 subjects treated with synthetic disease-modifying antirheumatic drugs and 19% with biologics. They noted inactive disease [indicated by juvenile arthritis disease activity (JADAS71) score <1] in 48% of participants. Despite new treatment options during the study period, they overall concluded that CR was not achieved with a high prevalence of the JIA cohort. They obtained the worst outcomes and a high burden of disease in adulthood for JIA with the ERA category.